Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan

Makhmujan Rashitov; Molly F. Franke; Letizia Trevisi; Gulzhanat Bekbolatova; Julia Shalimova; Gafurzhan Eshmetov; Sagit Bektasov; Allison LaHood; Nataliya Arlyapova; Elna Osso; Askar Yedilbayev; Oleksandr Korotych; Anisoara Ciobanu; Alena Skrahina; Carole D. Mitnick; Kwonjune J. Seung; Yerkebulan Algozhin; Michael Rich

doi:10.1093/cid/ciae305

Abstract

In 2019, WHO called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and effectiveness of three nine-month all-oral regimens containing bedaquiline (Bdq), linezolid (Lzd), and levofloxacin (Lfx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm) and pyrazinamide (Z), or Dlm and Cfz.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rashitov et al. (2024) studied this question.

synapsesocial.com/papers/68e66361b6db6435875f057a https://doi.org/10.1093/cid/ciae305

View Full Paper

Ask AI

Bookmark

Share

Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan

Abstract

Discussion

Cite This Study

Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan

Abstract

Discussion

Cite This Study

Keep reading

Keep reading